What is Fasting Glucose and Appropriate Targets for a 76-Year-Old with Type 2 Diabetes
For your 76-year-old patient with type 2 diabetes, A1C 8%, and moderately reduced renal function, a fasting plasma glucose target of 100-150 mg/dL is appropriate, with an A1C goal of <8.0%. 1, 2
Definition of Fasting Plasma Glucose
Fasting plasma glucose (FPG) is a blood glucose measurement obtained before the first meal of the day after a minimum 8-hour fast with no caloric intake. 3, 4 This measurement serves as both a diagnostic criterion for diabetes (≥126 mg/dL) and a key monitoring parameter for glycemic control. 5
Target Range for Your Specific Patient
Individualized A1C and Glucose Goals
Your patient falls into the "complex/intermediate" health category based on age (76 years) and moderately reduced renal function, warranting an A1C target of <8.0%. 1, 2 This less stringent goal is appropriate because:
- Advanced renal disease increases risk of hypoglycemia 6
- Older adults with comorbidities benefit from avoiding hypoglycemia more than achieving tight control 1, 2
- The risk-benefit ratio shifts away from aggressive glycemic control in this population 7
Specific Fasting Glucose Targets
To achieve an A1C of approximately 8%, the fasting plasma glucose should be maintained at 100-150 mg/dL. 1, 8 This range is derived from:
- The 2024 ADA Standards for Older Adults, which recommend fasting goals of 90-150 mg/dL for patients with intermediate complexity 1
- The Endocrine Society guidelines prioritizing blood glucose targets over A1C in older adults due to accuracy concerns and hypoglycemia risk 8
Supporting Evidence for These Targets
Research demonstrates that fasting glucose correlates with A1C achievement. 9 For an A1C target of 7.5-7.99%, the corresponding average fasting glucose is approximately 167 mg/dL (95% CI: 157-177 mg/dL). 9 However, given your patient's renal impairment and age, the more conservative 100-150 mg/dL range is safer. 1
Clinical Considerations for This Patient
Renal Function Impact
With moderately reduced renal function, metformin can be used safely if eGFR ≥30 mL/min/1.73 m². 1 However, medications should be selected carefully to minimize hypoglycemia risk, as renal impairment increases this risk substantially. 6
Avoiding Overtreatment
If the current A1C of 8% is being achieved with frequent hypoglycemia or complex insulin regimens, treatment simplification should be strongly considered. 1, 2 The 2024 ADA guidelines emphasize that regimen simplification is indicated when:
- Severe or recurrent hypoglycemia occurs (regardless of A1C) 2
- Wide glucose excursions are observed 2
- The patient cannot manage the complexity of the insulin regimen 1
Monitoring Approach
Continuous glucose monitoring (CGM) or blood glucose monitoring should be performed at least twice daily, particularly before insulin administration if used. 6 For this patient, a time-in-range (TIR) goal of 70-180 mg/dL of 50% with time-below-range <70 mg/dL of <1% would be appropriate if using CGM. 7
Common Pitfalls to Avoid
- Do not pursue an A1C <7% in this patient - the increased hypoglycemia risk outweighs any microvascular benefit given age and renal disease 6, 2
- Avoid relying solely on A1C - fasting glucose provides more actionable day-to-day targets and better identifies hypoglycemia risk 8
- Do not use sliding-scale insulin as the primary strategy - basal insulin with simplified regimens is preferred for older adults 1
- Monitor for medication accumulation - reduced renal function affects drug clearance, requiring dose adjustments for many diabetes medications 1